SFRP1 and hepatocellular carcinoma: Furthermore, they also demonstrated that sFRP1 promoter methylation decreased significantly compared to the HCC patients (48.2%), than in patients with cirrhotic liver (21.4%) and chronic hepatitis (14.3%).